# Phase II Panitumumab-IRDye800 in Head & Neck Cancer

> **NCT04511078** · PHASE2 · RECRUITING · sponsor: **University of Alabama at Birmingham** · enrollment: 25 (estimated)

## Conditions studied

- Head and Neck Cancer

## Interventions

- **DRUG:** Panitumumab-IRDye800

## Key facts

- **NCT ID:** NCT04511078
- **Lead sponsor:** University of Alabama at Birmingham
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-04-02
- **Primary completion:** 2030-12-31
- **Final completion:** 2030-12-31
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2025-12-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04511078

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04511078, "Phase II Panitumumab-IRDye800 in Head & Neck Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04511078. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*